GLP-1 dispensing in the UK in 2026 sits at the intersection of supply economics, regulatory nuance, and clinical responsibility. Compounded versus commercial preparations, prescriber discretion, NICE pathway alignment, and supply-chain volatility all shape what's actually possible on a given Tuesday. This piece is the operational map for clinics and brands dispensing GLP-1 medications.
The current UK supply landscape — Wegovy, Mounjaro, Ozempic
Tirzepatide (Mounjaro) and semaglutide (Wegovy/Ozempic) are prescription-only medicines in the UK with MHRA approval. Wegovy is manufactured by Novo Nordisk; Mounjaro is manufactured by Eli Lilly. Supply has been periodically constrained since 2023, with DHSC publishing multiple medicine supply notifications across the period.
Compounded GLP-1 — what 'specials' means and when it's legal
MHRA Specials regulations allow compounded preparations only where no licensed alternative meets the patient's need. Compounded semaglutide and tirzepatide are dispensed under this framework with full UK pharmacy oversight. Specials is not a workaround for supply shortages of commercial products and is not an unrestricted alternative.
Clinical assessment requirements specific to weight-management prescribing
GMC and GPhC require that weight-management prescribing follows recognised clinical pathways including BMI thresholds. Patient assessment must cover comorbidities, prior weight-loss attempts, contraindications, and ongoing-monitoring commitments. Asynchronous assessment is possible where clinically appropriate but red-flag escalation pathways must be in place.
Ongoing monitoring — what is required vs what is good practice
Required: dose-titration monitoring, adverse-event reporting via the Yellow Card scheme where indicated, ongoing prescribing-suitability reviews. Good practice: weight, blood pressure, lipid tracking, mental-health screening, patient-reported side-effect logging. The difference between required and good practice is increasingly the difference between defensible and indefensible clinical operations.
The ethics question — patient suitability, off-label use, supply rationing
Three ethics questions repeat in GLP-1 dispensing: is the patient genuinely suitable for the treatment under recognised pathways; is the prescribing within label or off-label; is the dispensing fair under supply constraints. Prescriber discretion applies. Brands that treat these as marketing questions rather than clinical questions create risk.
What changes in 2026 — pipeline, supply, regulation
The competitive pipeline for GLP-1 receptor agonists is significant. Multiple new molecules and combination products are in late-stage development. The medium-term outlook is more supply, more dose options, and gradually decreasing per-patient costs. Short-term volatility remains likely. Regulators are paying close attention to advertising claims.
GLP-1 is the most strategically important category for many UK telehealth brands right now. Treat dispensing as a clinical decision with commercial consequences — not the other way around.
Specials is not a workaround for supply shortages of commercial products. Treat it as the narrow legal route it is.
GLP-1 dispensing in 2026 rewards clinical discipline. The brands and clinics that treat it as a regulated clinical activity — with all the structural requirements that implies — build durable operations. The ones that treat it as ecommerce build fragile ones.
